Effects of Clinical Characteristics, Laboratory Parameters and Treatment Regimens on Prognosis of Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2019.04.028
- Author:
Lu XU
1
;
Zhi-Lin CHEN
2
;
Min HU
1
;
Shi TAO
1
;
Yu CHEN
1
;
Gang-Hao SU
3
Author Information
1. Department of Hematology and Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou 570000, Hainan Province, China.
2. Department of Breast Tumor Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou 570000, Hainan Province, China.
3. Department of Hematology and Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou 570000, Hainan Province, China,E-mail: 510199898@qq.com.
- Publication Type:Journal Article
- MeSH:
Amyloidosis;
Humans;
Multiple Myeloma;
Prognosis;
Retrospective Studies;
Thalidomide
- From:
Journal of Experimental Hematology
2019;27(4):1166-1172
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effects of clinicopathological features, laboratory parameters and treatment regimens on the prognosis of patients with multiple myeloma.
METHODS:The clinical data of 97 patients with multiple myeloma treated with chemotherapy in Department of Hematology, the 1st Hospital of Hainan Medical College were analyzed retrospectively. The clinicopathological features (age, sex, severe anemia, light chain type, hypoproteinemia, paraplegia, renal injury, amyloidosis, complex karyotype, bone disease classification, Eastern Cooperative Oncology Group (ECOG) physical status score, complete remission, etc.), laboratory parameters (C-reactive protein, lactate dehydrogenase, blood calcium, serum β2 microglobulin, etc.), and treatment schemes (thalidomide maintenance treatment) were recorded. The patients were followed up for 1-60 months, and their total survival time were recorded. A single factor and multiple factors were used to analyze the factors affecting the total and early mortality of the patients. The survival curves were plotted by the Kaplan-Meier method and the survival analysis was carried out by Log-rank test.
RESULTS:Among 97 patients, 29 cases (29.90%) achieved complete remission, and 56 cases (57.73%) achineved partial remission. The total effective rate was 87.63% (85/97). At the end of the follow-up, 19 cases (19.59%) died, and 1, 3 and 5 year survival rates were 80.41%, 71.13% and 37.11% respectively. The median overall survival time was 29 (1-60) months. The results of single factor analysis showed that age, hypoproteinemia, severe anemia, paraplegia, renal injury, amyloidosis, complex karyotype, complete remission and thalidomide maintenance therapy were the factors affecting the prognosis of the patients (all P＜0.05). Further multiple factor Logistic regression analysis showed that age and hypoproteinemia, severe anemia, paraplegia, amyloidosis, complex karyotype and thalidomide maintenance treatment were factors affecting the prognosis (P＜0.05). Of the 97 patients, 8 cases died early. The results of single factor analysis showed that amyloidosis and severe anemia were risk factors for early death (all P＜0.05), and further multivariate Logistic regression analysis showed that amyloidosis was an independent risk factor for early death (P＜0.05).
CONCLUSION:There are many adverse factors affecting the prognosis of patients with multiple myeloma, such as age, hypoproteinemia, severe anemia, paraplegia, amyloidosis, complex karyotype and so on. The risk of early death in the patients with amyloidosis is higher, and salidomide maintenance therapy can help to prolong the life span of the patient.
